What is Waldenström’s macroglobulinaemia?

Waldenström’s macroglobulinaemia (WM) is a type of blood cancer. It is sometimes called lymphoplasmacytic lymphoma.

WM develops when blood cells called lymphocytes become abnormal. These blood cells normally help fight infection.

The abnormal lymphocytes usually build up in the bone marrow, lymph nodes, spleen and other organs. Sometimes this can make the spleen or lymph nodes bigger.

As the abnormal cells build up in the body, they make large amounts of a protein. This protein has several names:

  • immunoglobulin M or IgM
  • M-protein or M-band
  • paraprotein.

The protein circulates in the blood. Large amounts of it can cause the blood to become thicker and move slowly.

    Booklets and resources

    Symptoms of Waldenström’s macroglobulinaemia

    WM usually develops slowly. It may not cause any symptoms for a long time.

    The most common WM symptoms are:

    • feeling weak and tired (fatigue)
    • feeling mentally slow or ‘foggy’
    • anaemia – this is caused by a low number of red blood cells in the blood
    • bruising or bleeding easily – this is caused by a low number of blood-clotting cells (platelets) in the blood
    • repeated infections – this is caused by a lack of healthy white blood cells which help fight infection
    • heavy, drenching night sweats
    • weight loss.

    Other symptoms

    Other symptoms may include:

    • numbness or tingling in the hands and feet
    • headaches
    • confusion
    • blurred vision
    • problems with balance.

    Worried about symptoms?

    A change in how you feel or how your body works can be caused by conditions other than WM. But always ask your GP to check any ongoing, new or unexplained symptoms.

    We are also here if you need someone to talk to. You can:

    Related pages

    Causes of Waldenström’s macroglobulinaemia

    The causes of WM are mostly unknown. We have more general information about the causes and risk factors of non-Hodgkin lymphoma.

    WM is more common in people over 65. It is slightly more common in men than women.

    Like other cancers, WM is not infectious. You cannot spread it to other people.

    MGUS and other conditions

    WM is sometimes linked to a blood condition called monoclonal gammopathy of unknown significance (MGUS).

    WM is sometimes linked to other health conditions such as:

    • Sjogren syndrome
    • autoimmune haemolytic anaemia
    • B-cell lymphomas.

    If you or a family member has one of these conditions, you may have a higher than average risk of developing WM. But because WM is rare, your risk is still very low.

    Diagnosis of Waldenström’s macroglobulinaemia

    WM often develops slowly and causes few symptoms to start with. It might be found during blood tests for some other reason.

    The most important test for diagnosing WM is a bone marrow test.

    You may have blood and bone marrow tests to look at the genes in the lymphoma cells. Around 9 out of 10 people with WM (90%) have a genetic change (mutation) called MYD88. Your cancer doctor or specialist nurse can tell you more about this.

    You may have further tests to check how WM is affecting you. For example, you may have a scan to check your liver, spleen or lymph nodes throughout your body.

    You can read more about the tests you may have in general lymphoma information.

    Waiting for test results

    Waiting for test results can be a difficult time. It may take up to 2 weeks for the results to be ready.

    You may find it helpful to talk to family members or a close friend. Your specialist nurse can also provide support.

    You can talk to one of our cancer support specialists for free on 0808 808 0000, 7 days a week, 8am to 8pm.

    Booklets and resources

    Test results for Waldenström’s macroglobulinaemia

    Your test results give your cancer team more information about the lymphoma. This includes the:

    • level of red blood cells in the blood
    • number of blood-clotting cells (platelets) in the blood
    • amount of IgM in the blood
    • amount of a protein called beta-2-microglobulin in the blood
    • grade of WM.

    Grading describes how and how quickly the lymphoma cells are likely to grow. WM is a low grade lymphoma. This means it usually develops slowly. Rarely it can change (transform) into high grade lymphoma. High grade lymphoma grows more quickly and needs treatment straight away.

    These factors help your cancer team:

    • predict how the lymphoma may behave
    • plan the right treatment for you.

    Treatment for Waldenström's macroglobulinaemia

    A team of specialists will meet to discuss the best possible treatment for you. They are called a multidisciplinary team (MDT).

    After the MDT meeting, you will usually meet with your cancer doctor and specialist nurse. They will talk to you about:

    • whether you need treatment straight away
    • the different treatment options and their side effects
    • things to consider when making treatment decisions.

    WM often develops slowly. If you have no symptoms, you may not need any treatment.

    Instead, you will have regular tests and appointments to monitor the lymphoma and check for signs that you need to start treatment. This is called watch and wait. It may also be called active surveillance or active monitoring. It is a way of safely delaying treatment until you need it.

    You may start treatment if:

    • you have symptoms that are causing problems
    • the level of IgM protein in your blood is continually increasing
    • your blood count changes – for example, if you have low levels of red blood cells (anaemia).

    The aim of treatment is to improve your quality of life and keep you well for as long as possible, with the fewest possible side effects. You can have most treatments for WM as an outpatient. You may have some treatments as part of a clinical trial.

    Cancer drug treatment

    WM is often treated with cancer drugs. Treatment usually includes an immunotherapy drug called rituximab in combination with other cancer drugs. For example, combinations that may be used include:

    Other drugs may be used. Your cancer team will give you information about your treatment plan. Some newer drugs may only be available in some situations. If a drug is not routinely available on the NHS, there may be other ways you can get access to it.

    Treatment for WM symptoms

    You may also have treatments for symptoms of WM:

    • Blood transfusions

      If you have symptoms caused by a low number of red blood cells, you may have a blood transfusion.

    • Plasma exchange

      If tests show that protein levels are thickening your blood, you may have plasma exchange treatment. This treatment removes some of the paraprotein and helps to thin the blood. It is also called plasmapheresis. You usually have it as an outpatient at a clinic. It takes a few hours.

    Treating WM relapse

    Treatment for WM can be very effective. It may make all signs of lymphoma disappear for a time. But this type of lymphoma usually comes back after treatment. This is called recurrence or relapse.

    If you have a relapse, you can usually have more cancer drug treatment to help control it again. This may include targeted therapy drugs such as zanubrutinib or ibrutinib. Your cancer team will explain which drugs are suitable for you.

    Sometimes WM is treated with intensive treatment that involves a stem cell transplant. This treatment has a risk of more serious side effects and is not suitable for everyone. Your cancer team can give you more information.

    Treating transformed WM

    Sometimes WM can change from low grade into high grade lymphoma. This is called transformation or transformed WM. It is not common. But your cancer team will do tests to check for this when you are diagnosed or have a relapse of WM.

    High grade lymphoma grows more quickly and is treated differently. Transformed WM is treated in the same way as another type of lymphoma called DLBCL.

    After treatment for Waldenström’s macroglobulinaemia

    Follow-up after treatment for WM

    You will have regular check-ups during and after your treatment for WM. Your cancer doctor or specialist nurse will explain what to expect.

    Follow-up appointments are a good time for you to talk to your cancer doctor or specialist nurse about any concerns you have. Tell them as soon as possible if you have any problems or notice new symptoms between appointments. We have more information about follow-up care after treatment.

    Sometimes side effects may continue or develop months or years after treatment. These are called late effects. We have more information about late effects of lymphoma treatment.

    Wellbeing and recovery

    Looking after yourself can help speed up your recovery after WM treatment. Even small lifestyle changes may improve your wellbeing and long term health.

    Even if you already have a healthy lifestyle, you may choose to make some positive changes after treatment. We have more information on leading a healthy lifestyle after treatment.

    Support for people with Waldenström's macroglobulinaemia

    People often have many different feelings during and after WM treatment. If you have finished treatment, you may feel relieved it has ended but worried about what might happen in the future.

    It is important to know where to get support or information if you need it. People often need support even some time after WM treatment. But sometimes it is difficult to know who to ask for help.

    You can:

    You may also find the HOPE programme helpful. The programme is a free 6 week self-management course designed to help you develop techniques and strategies when living with or after cancer. Topics include goal setting, fatigue management, and wellbeing.

    You can sign up for the online HOPE programme. Or to find out more about face to face programmes in your area, email ServiceOpsSupport@macmillan.org.uk

    Other organisations who offer information and support

    • Blood Cancer UK offers support and information to people affected by blood cancers, including lymphoma.
    • Lymphoma Action provides high quality information and support for people affected by lymphoma. It provides helpline services and a range of peer support including online support meetings, educational events and webinars. Its website includes TrialsLink, a database of lymphoma clinical trials.

    More information and advice

    We know cancer can affect you physically, emotionally and financially. We have information and advice about different ways cancer might impact you, such as help with:

    About our information

    This information has been written, revised and edited by Macmillan Cancer Support’s Cancer Information Development team. It has been reviewed by expert medical and health professionals and people living with cancer.

    • References

      Below is a sample of the sources used in our lymphoma information. If you would like more information about the sources we use, please contact us at informationproductionteam@macmillan.org.uk

       

      Cwynarski K, Marzolini MAV, Barrington SF, et al. The management of primary mediastinal B-cell lymphoma: a British Society for Haematology Good Practice Paper. Br J Haematol. 2019;185:402-9.

       

      Eyre TA, Bishton MJ, McCulloch R, et al. Diagnosis and management of mantle cell lymphoma: A British Society for Haematology Guideline. Br J Haematol. 2024;204(1):108–26.

       

      Ferreri AJM, Illerhaus G, Doorduijn K, et al., on behalf of the EHA and ESMO Guidelines Committees. Primary central nervous system lymphomas: EHA–ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2024;35(6):491-507.

       

      Fox CP, Ahearne MJ, Pettengell R, et al. Guidelines for the management of mature T- and natural killer-cell lymphomas (excluding cutaneous T-cell lymphoma): a British Society for Haematology Guideline. Br J Haematol. 2022;196:507-22.

       

      Fox CP, Chaganti S, McIlroy G, et al. The management of newly diagnosed large B-cell lymphoma: A British Society for Haematology Guideline. Br J Haematol. 2024;204(4):1178–92.

       

      McNamara C, Montoto S, Eyre TA, et al. The investigation and management of follicular lymphoma. Br J Haematol. 2020;191:363-81.

       

      Pratt G, El-Sharkawi D, Kothari J, et al. Diagnosis and management of Waldenström macroglobulinaemia—A British Society for Haematology guideline. Br J Haematol. 2022;197:171–87.

       

      Walewska R, Eyre TA, Barrington S, et al. Guideline for the diagnosis and management of marginal zone lymphomas: A British Society of Haematology Guideline. Br J Haematol. 2024;204(1):86–107.

    Date reviewed

    Reviewed: 01 February 2025
    |
    Next review: 01 February 2028
    Trusted Information Creator - Patient Information Forum
    Trusted Information Creator - Patient Information Forum

    Our cancer information meets the PIF TICK quality mark.

    This means it is easy to use, up-to-date and based on the latest evidence. Learn more about how we produce our information.

    The language we use


    We want everyone affected by cancer to feel our information is written for them.


    We want our information to be as clear as possible. To do this, we try to:

    • use plain English
    • explain medical words
    • use short sentences
    • use illustrations to explain text
    • structure the information clearly
    • make sure important points are clear.

    We use gender-inclusive language and talk to our readers as ‘you’ so that everyone feels included. Where clinically necessary we use the terms ‘men’ and ‘women’ or ‘male’ and ‘female’. For example, we do so when talking about parts of the body or mentioning statistics or research about who is affected.


    You can read more about how we produce our information here.